Gilead Sciences Announces Changes to Cardiovascular R&D Organization Leadership

FOSTER CITY, Calif.--(BUSINESS WIRE)--May. 22, 2009-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced, as part of the ongoing integration of CV Therapeutics, changes to the company’s cardiovascular research and development organization leadership. Louis G. Lange, MD, PhD has decided to assume a part-time position at Gilead and will therefore be transitioning from his role as Executive Vice President, Cardiovascular Therapeutics.

With this transition, Gilead’s cardiovascular research and development organization will report to Norbert Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer. Luiz Belardinelli, MD, Senior Vice President, Cardiovascular Therapeutics, will serve as therapeutic area head for cardiovascular therapeutics, based in Palo Alto and reporting to Dr. Bischofberger.

“Lou has played an integral role in the newly combined Gilead organization, helping us achieve significant progress with integration of our cardiovascular R&D operations. In his new role, Lou will continue to provide valuable insight and input into our research and development programs in cardiovascular disease,” said John C. Martin, PhD, Chairman and Chief Executive Officer. “Under Norbert’s leadership, I am confident that we will be able to advance clinical and research programs as efficiently as possible, and ultimately bring forward new therapies that represent significant advancements for patients.”

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risks related to our ability to advance product candidates in our pipeline. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the first quarter of 2009, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)